Yi-Shi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi-Shi Wu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Limei Fan
Department of Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People’s Republic of China
1 shared publication- Manhua Cui
Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
1 shared publication Miaomiao Fu
Department of Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People’s Republic of China
1 shared publicationRuimin Zhao
Department of Gynecology, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People’s Republic of China
1 shared publication- Tianmin Xu
Department of Gynaecology and Obstetrics, The Bethune Second Hospital of Jilin University, Changchun, P.R. China
1 shared publication - Xi-Wen Zhang
Department of Gynecology, The Second Hospital of Jilin University, Changchun 130000, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 12263-12281
Advances in Nanotechnology in the Diagnosis and Treatment of Gynecological Cancers
Nanotechnology platforms facilitate therapeutic drug delivery and offer various advantages over conventional drugs, such as biocompatibility, non-inflammatory effects, high therapeutic output, biodegradability, non-toxicity, and biocompatibility. Due to the inherent drawbacks of conventional drug delivery to cancerous tissues, nanotechnology-based alternatives have been developed for such diseases. Gynecologic malignant tumors (GCs), include various types of cervical, endometrial, and ovarian cancers. The epidemiological characteristics of the tumors show that their incidence is increasing significantly and tends to be younger, which is a serious threat to women’s physical and mental health. This article provides a systematic review of the latest research results on nanomaterials in the diagnosis and treatment of gynecological malignancies, including 2 sections on nanomaterials-based diagnostic and therapeutic strategies in gynecological cancers. In particular, the article also analyzes the challenges faced by nanotechnology, including toxicity, technology, and clinical translation issues. These applications not only improve the therapeutic efficacy of gynecological cancers, but also reduce the toxicity and side effects, and provide a new direction for the precise treatment of gynecological cancers.
- 1 October 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 12263-12281
Open AccessAdvances in Nanotechnology in the Diagnosis and Treatment of Gynecological Cancers
Nanotechnology platforms facilitate therapeutic drug delivery and offer various advantages over conventional drugs, such as biocompatibility, non-inflammatory effects, high therapeutic output, biodegradability, non-toxicity, and biocompatibility. Due to the inherent drawbacks of conventional drug delivery to cancerous tissues, nanotechnology-based alternatives have been developed for such diseases. Gynecologic malignant tumors (GCs), include various types of cervical, endometrial, and ovarian cancers. The epidemiological characteristics of the tumors show that their incidence is increasing significantly and tends to be younger, which is a serious threat to women’s physical and mental health. This article provides a systematic review of the latest research results on nanomaterials in the diagnosis and treatment of gynecological malignancies, including 2 sections on nanomaterials-based diagnostic and therapeutic strategies in gynecological cancers. In particular, the article also analyzes the challenges faced by nanotechnology, including toxicity, technology, and clinical translation issues. These applications not only improve the therapeutic efficacy of gynecological cancers, but also reduce the toxicity and side effects, and provide a new direction for the precise treatment of gynecological cancers.
- Open Access
- 2 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 465
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.
- 2 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 465
Open AccessCAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.